Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Ha | - |
dc.contributor.author | Shin, Dae Hwan | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.date.available | 2021-02-22T08:46:14Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/4425 | - |
dc.description.abstract | A docetaxel (DTX) liposomal formulation composed of egg phosphatidylcholine, sodium deoxycholate, and stearylamine was developed. Eudragit (0.5%) was coated to deliver the drug to the region between the distal small intestine and the colon. Lyophilized trehalose and mannitol were used as cryoprotectants because they preserve the particle integrity and good appearance. In vitro release studies showed that the amount of drug released from the coated liposomes was low in solution 1, which simulated the pH condition of the stomach. Especially during the average gastric emptying time, the amount of drug released decreased when Eudragit was added. The plasma DTX concentration was evaluated in pharmacokinetic studies. The plasma drug concentration after intravenous (i.v.) administration decreased rapidly within 120 min. Free DTX formulated using Tween 80 and the lyophilized Eudragit-coated liposomal formulation were compared after oral administration. The oral liposomal formulation had a longer half-life (t(1/2)) and three-fold higher oral bioavailability. Thus, lyophilized Eudragit-coated liposomal DTX could be a promising therapy for various solid tumors to improve patient convenience and quality of life. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.1007/s12272-018-1046-y | - |
dc.identifier.scopusid | 2-s2.0-85049192314 | - |
dc.identifier.wosid | 000440309800007 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.41, no.7, pp 765 - 775 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 41 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 765 | - |
dc.citation.endPage | 775 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002372796 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordPlus | LYOPHILIZATION | - |
dc.subject.keywordPlus | NANOMEDICINES | - |
dc.subject.keywordPlus | FORMULATIONS | - |
dc.subject.keywordPlus | IMPROVEMENT | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Eudragit | - |
dc.subject.keywordAuthor | Oral liposome | - |
dc.subject.keywordAuthor | Pharmacokinetic | - |
dc.subject.keywordAuthor | TEM | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s12272-018-1046-y | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.